×
Supernus Pharmaceuticals EBIT 2011-2024 | SUPN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Supernus Pharmaceuticals ebit from 2011 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Supernus Pharmaceuticals EBIT 2011-2024 | SUPN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Supernus Pharmaceuticals ebit from 2011 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$19B
Dr Reddy's Laboratories (RDY)
$12B
BridgeBio Pharma (BBIO)
$4.3B
Bausch Health Cos (BHC)
$3B
Amphastar Pharmaceuticals (AMPH)
$2.1B
Taysha Gene Therapies (TSHA)
$434M
Personalis (PSNL)
$261M
Assembly Biosciences (ASMB)
$98M
Sol-Gel Technologies (SLGL)
$12M
Evoke Pharma (EVOK)
$7M
Teligent (TLGT)
$0M